Darizmetinib

Description: Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. Target: Antiviral, MAPK. Smiles: O=C(C1=NNC2=NC=C(C=C21)C=3C=CN=CC3)C4=CC=C(F)C(NS(=O)(=O)CCC)=C4F. References: Praefke B, et al. Preparation of pyrazolopyridines as protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death: World Intellectual Property Organization, WO2019149738. 2019-08-08.